Array posts $147M loss for fiscal year; launches two-drug combination

BOULDER — Array BioPharma Inc. (Nasdaq: ARRY) on Tuesday reported a loss of $147.3 million for its fiscal year that ended June 30.

The loss of 74 cents per share was more that a loss of $116.8 million, or 72 cents per share, in fiscal 2017. The increase in loss primarily was because of  increased research and development expense to advance programs and costs to establish the commercial infrastructure in preparation of the launch of two drugs, Braftovi and Mektovi.

Revenue was $173.8 million for the fiscal year compared with $150.9 million in fiscal 2017. This…